- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Evoq Remedies Board approved H1 FY26 results: Revenue 26.57 Cr, Profit 0.05 Cr. Auditors highlighted significant concerns, including SEBI investigations regarding financials and fund use, unresolved advances, and tax disputes. Reliability of financial reporting questioned.